" class="no-js "lang="en-US"> LovedBy Hires Former AXA Health Executive Arup Paul as Clinical Director - Medtech Alert
Friday, April 12, 2024

LovedBy Hires Former AXA Health Executive Arup Paul as Clinical Director

LovedBy, a technology and consultancy business that exists to improve the lives of people, their families, and communities, today announces the appointment of Dr Arup Paul as its Clinical Director. Dr Paul, who joins from AXA Health where he was Deputy Chief Medical Officer, will be responsible for galvanising LovedBy’s clinical direction as it moves to become a leading provider of global Gen Z healthcare.

LovedBy has developed a ‘short-form content’ behavioural health platform, Nudg, to improve the health and wellbeing of adolescents and young people living with chronic conditions such as asthma and type-one diabetes. Designed with young people, for young people, the platform brings together behavioural science, technology and design to deliver engaging content that encourages behaviour change and more effective condition management for a unique diverse and digital-first demographic.

Dr Paul brings extensive experience from across hospital medicine, general practice and senior leadership roles within the healthcare industry, having previously chaired the Locality Commissioning Group for NHS Professionals, sat on the Primary Care Transformation Board of NHS England, and served as Chief Operating Officer and Chief Medical Officer simultaneously at HCML Rehabilitation Solutions. His deep understanding of the immense variance of clinical needs and access to quality care will be invaluable to LovedBy in developing a personalised, human-centric approach to healthcare.

In his new role, Dr Paul will define and drive forward LovedBy’s clinical approach, ensuring the company remains at the forefront of personalised, effective healthcare delivery. He will focus on developing innovative strategies, collaborations and partnerships that will allow LovedBy to continue growing, and establishing clinical integration opportunities with other healthcare delivery systems and providers, to deliver affordable outcomes.

Matt Farrar, CEO of LovedBy, comments:

“I am extremely excited to be working with Arup. He brings years of public health and commercial experience to the table, which will be extremely valuable to our business – as will his passions for ethics, behavioural science, social mobility, and patient inclusion and accessibility, which are core to LovedBy’s proposition. We have worked with some exceptional clinicians across asthma, type-one diabetes and mental health since our inception, and it’s fantastic to have Arup join us as we continue to grow the knowledge and IP driving our business.”

Dr Arup Paul, Clinical Director of LovedBy, says:

“I’m delighted to be working with Matt and the team at LovedBy. We’re at a unique inflection point in healthcare where the intersection between data, technology, the importance of personalisation and enhancing patient agency has never been more important. Underpinning this all must be trust and integrity, so it’s a privilege to join a team with such a strong sense of purpose and ethical code. I look forward to supporting LovedBy in developing services that deliver real value to people, with understanding, nuance and empathy.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more